Literature DB >> 18828138

Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.

Florence A Castelli1, Diane Houitte, Gaetan Munier, Natacha Szely, Alain Lecoq, Jean-Paul Briand, Sylviane Muller, Bernard Maillere.   

Abstract

Recent studies have suggested including nonstructural proteins as Tat and Vpr in HIV vaccines. However, little is known about the CD4+ T-cell response that these small proteins induce in humans. We have therefore evaluated these responses by in vitro priming experiments of CD4+ T lymphocytes harvested in healthy donors. In the Tat protein, only one peptide primed CD4+ T cells of eight HLA unrelated healthy donors. T cells induced by this peptide recognized immature DC loaded with the native Tat protein and are restricted by multiple HLA-DR molecules, in agreement with its binding capacity. This peptide was therefore processed in an appropriate manner and was highly immunoprevalent. CD4+ T-cell response to Vpr peptides was more disperse and involved six different peptides depending on the HLA-DR molecules of the donors. Two overlapping peptides were T-cell stimulating in at least half of the donors. T-cell response to Vpr in multiple donors is the result of a combination of several CD4+ T-cell epitopes with good to moderate immunoprevalence. Altogether, our results show that the frequency of responders to HIV Tat or Vpr proteins relies on one or multiple CD4+ T-cell epitopes, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18828138     DOI: 10.1002/eji.200738072

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells.

Authors:  Bonnie A Colleton; Xiao-Li Huang; Nada M Melhem; Zheng Fan; Luann Borowski; Giovanna Rappocciolo; Charles R Rinaldo
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

2.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

3.  Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Authors:  Adam J Ritchie; Suzanne L Campion; Jakub Kopycinski; Zoe Moodie; Z Maggie Wang; Kruti Pandya; Stephen Moore; Michael K P Liu; Simon Brackenridge; Kristin Kuldanek; Kenneth Legg; Myron S Cohen; Eric L Delwart; Barton F Haynes; Sarah Fidler; Andrew J McMichael; Nilu Goonetilleke
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.

Authors:  Moustafa Hamze; Sylvain Meunier; Anette Karle; Abdelaziz Gdoura; Amélie Goudet; Natacha Szely; Marc Pallardy; Franck Carbonnel; Sebastian Spindeldreher; Xavier Mariette; Corinne Miceli-Richard; Bernard Maillère
Journal:  Front Immunol       Date:  2017-05-05       Impact factor: 7.561

5.  Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses.

Authors:  Aurélien Azam; Sergio Mallart; Stephane Illiano; Olivier Duclos; Catherine Prades; Bernard Maillère
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

6.  Human CD4 T cell epitopes selective for Vaccinia versus Variola virus.

Authors:  Alicia Probst; Aurore Besse; Emmanuel Favry; Gilles Imbert; Valérie Tanchou; Florence Anne Castelli; Bernard Maillere
Journal:  Mol Immunol       Date:  2012-11-10       Impact factor: 4.174

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.